ArticleJournal of the American Chemical Society2012
Single siRNA nanocapsules for enhanced RNAi delivery.
Article in Journal of the American Chemical Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 65 citations in OpenAlex.
- A First-In-Human Phase 1 Study to Evaluate the Safety and Tolerability of LEM-S401, a Novel siRNA-DegradaBALL Drug Targeting CTGF in Healthy Adults.Clinical and translational science · 2025Trial
- Innovative Formulation Platform: Paving the Way for Superior Protein Therapeutics with Enhanced Efficacy and Broadened Applications.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Multiplexed shRNA-miRs as a candidate for anti HIV-1 therapy: strategies, challenges, and future potential.Journal, genetic engineering & biotechnology · 2022Review
- Targeted Nanocarrier Delivery of RNA Therapeutics to Control HIV Infection.Pharmaceutics · 2022Review
- Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application.Pharmaceutics · 2022Review
- Nanoparticles for protein delivery in planta.Current opinion in plant biology · 2021Review
- Crosslinked polymer nanocapsules for therapeutic, diagnostic, and theranostic applications.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Complex polymer architectures through free-radical polymerization of multivinyl monomers.Nature reviews. Chemistry · 2020Review
- Strategies, design, and chemistry in siRNA delivery systems.Advanced drug delivery reviews · 2019Review
- Enhancing the In Vitro and In Vivo Stabilities of Polymeric Nucleic Acid Delivery Nanosystems.Bioconjugate chemistry · 2019Review
- A multifunctional DNA nano-scorpion for highly efficient targeted delivery of mRNA therapeutics.Scientific reports · 2018Article
- Nanotechnological Strategies for Protein Delivery.Molecules (Basel, Switzerland) · 2018Review
- Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2017Review
- Injectable, Guest-Host Assembled Polyethylenimine Hydrogel for siRNA Delivery.Biomacromolecules · 2017Article
- A DNA dual lock-and-key strategy for cell-subtype-specific siRNA delivery.Nature communications · 2016Article
- Porous silicon-graphene oxide core-shell nanoparticles for targeted delivery of siRNA to the injured brain.Nanoscale horizons · 2016Article
- Specific Elimination of Latently HIV-1 Infected Cells Using HIV-1 Protease-Sensitive Toxin Nanocapsules.PloS one · 2016Article
- Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy.Molecular pharmaceutics · 2015Review
- Modulation of Gene Expression by Polymer Nanocapsule Delivery of DNA Cassettes Encoding Small RNAs.PloS one · 2015Article
- RNA interference approaches for treatment of HIV-1 infection.Genome medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Synthetic siRNA has been considered as a highly promising therapeutic agent for human diseases. However, clinical use of siRNA has been hampered by instability in the body and inability to deliver sufficient RNA interference compounds to the tissues or cells. To address this challenge, we present here a single siRNA nanocapsule delivery technology, which is achieved by encapsulating a single siRNA molecule within a degradable polymer nanocapsule with a diameter around 20 nm and positive surface charge. As proof-of-concept, since CCR5 is considered a major silencing target of HIV therapy, CCR5-siRNA nanocapsules were delivered into 293T cells and successfully downregulated the CCR5 RNA fused with mCherry reporter RNA. In the absence of human serum, nanocapsules and lipofectamine silenced expression of CCR5-mCherry expression to 8% and 15%, respectively. Such nanocapsules maintain the integrity of siRNA inside even after incubation with ribonuclease and serum for 1 h; under the same conditions, siRNA is degraded in the native form or when formulated with lipofectamine. In the presence of serum, CCR5-siRNA nanocapsules knocked down CCR5-mCherry expression to less than 15% while siRNAs delivered through lipofectamine slightly knocked down the expression to 55%. In summary, this work provides a novel platform for siRNA delivery that can be developed for therapeutic purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.